Latest News and Press Releases

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Vera Therapeutics announces proposed public offering of Class A common stock.

Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4).

Vera Therapeutics appoints veteran biotech executive James R. Meyers to its Board of Directors.

Vera Therapeutics' management team will present and participate in one-on-one meetings at upcoming investor conferences.

Vera Therapeutics' management team will present at the TD Cowen Immunology & Inflammation Summit (Nov. 12-13, 2025).

Vera Therapeutics Submits BLA to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgAN

BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera...

Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week...

Vera Therapeutics today reported its business highlights and financial results for the third quarter ended September 30, 2025